Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$182.60 USD
-3.99 (-2.14%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $182.89 +0.29 (0.16%) 7:20 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASND 182.60 -3.99(-2.14%)
Will ASND be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Other News for ASND
What's Driving the Market Sentiment Around Ascendis Pharma?
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
Franklin Biotechnology Discovery Fund Q2 2025 Commentary